# Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

Study · id `cardio:ct-nct02113332` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02113332](<https://clinicaltrials.gov/study/NCT02113332>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02113332

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

## Technical summary

Registry record NCT02113332. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 124 participants (enrolled count; ClinicalTrials.gov record NCT02113332, source copy `cardio:ctgov-nct02113332-2015-02-03`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT02113332, source copy `cardio:ctgov-nct02113332-2015-02-03`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT02113332, source copy `cardio:ctgov-nct02113332-2015-02-03`, retrieved 2026-10-26)
- Completion: 2014-08 (actual) (ClinicalTrials.gov record NCT02113332, source copy `cardio:ctgov-nct02113332-2015-02-03`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT02113332, source copy `cardio:ctgov-nct02113332-2015-02-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02113332-2015-02-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Liraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Vastra Gotaland Region
- Lead sponsor class: OTHER\_GOV
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Vastra Gotaland Region (`cardio:org-vastra-gotaland-region`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: abfe8bccd56d79463ab89ef826b0ab72454021fc9d9377debe2eea5dadf7ceec
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
